Patents by Inventor Michael C. Jensen

Michael C. Jensen has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20210346431
    Abstract: The present disclosure relates to methods of treating a patient with a cancer by administering to the patient a composition comprising CAR T cells and administering to the patient a small molecule linked to a targeting moiety by a linker. The disclosure also relates to compositions for use in such methods.
    Type: Application
    Filed: February 22, 2019
    Publication date: November 11, 2021
    Inventors: Richard MESSMANN, Christopher Paul LEAMON, Haiyan CHU, Yingjuan June LU, Philip Stewart LOW, Michael C. JENSEN, James MATTHAEI, Navin Robert Charles PINTO, Julie Ruggieri PARK
  • Patent number: 11160833
    Abstract: A CD19-OR-CD20 chimeric antigen receptor (CAR) protein construct is provided. Also provided are nucleic acids encoding the CD19-OR-CD20 CAR; and methods of use, e.g. in the treatment of B cell malignancies. The CD19-OR-CD20 CAR of the invention is a bispecific CAR that can trigger T-cell activation upon detection of either CD19 or CD20 (or both). It is a single molecule that confers two-input recognition capability upon human T cells engineered to stably express this CAR.
    Type: Grant
    Filed: September 22, 2020
    Date of Patent: November 2, 2021
    Assignees: The Regents of the University of California, Seattle Children's Hospital
    Inventors: Yvonne Y. Chen, Eugenia Zah, Michael C. Jensen
  • Patent number: 11155783
    Abstract: A non-immunogenic selection epitope may be generated by removing certain amino acid sequences of the protein. For example, a gene encoding a truncated human epidermal growth factor receptor polypeptide (EGFRt) that lacks the membrane distal EGF-binding domain and the cytoplasmic signaling tail, but retains an extracellular epitope recognized by an anti-EGFR antibody is provided. Cells may be genetically modified to express EGFRt and then purified without the immunoactivity that would accompany the use of full-length EGFR immunoactivity. Through flow cytometric analysis, EGFRt was successfully utilized as an in vivo tracking marker for genetically modified human T cell engraftment in mice. Furthermore, EGFRt was demonstrated to have cellular depletion potential through cetuximab mediated antibody dependent cellular cytotoxicity (ADCC) pathways.
    Type: Grant
    Filed: October 15, 2018
    Date of Patent: October 26, 2021
    Assignee: City of Hope
    Inventor: Michael C. Jensen
  • Patent number: 11155616
    Abstract: The present invention provides nucleic acids, vectors, host cells, methods and compositions to confer and/or augment immune responses mediated by cellular immunotherapy, such as by adoptively transferring CD8+ central memory T cells or combinations of central memory T cells with CD4+ T cells that are genetically modified to express a chimeric receptor under the control of an inducible promoter. In some alternatives the genetically modified host cell comprises a nucleic acid comprising a polynucleotide coding for a chimeric antigen receptor comprising a ligand binding domain, a polynucleotide comprising a spacer region, a polynucleotide comprising a transmembrane domain, and a polynucleotide comprising an intracellular signaling domain under the control of a drug inducible promoter. Controlling the expression of the chimeric receptor provides for the ability to turn expression on and off depending on the status of the patient.
    Type: Grant
    Filed: February 27, 2019
    Date of Patent: October 26, 2021
    Assignee: Seattle Children's Hospital
    Inventor: Michael C. Jensen
  • Publication number: 20210324083
    Abstract: Embodiments of the methods and compositions provided herein relate to chimeric antigen receptors (CARs) that specifically bind to B7H3. Some embodiments relate to cell-based immunotherapy targeting tumors, such as tumors comprising B7H3+ cells.
    Type: Application
    Filed: August 29, 2019
    Publication date: October 21, 2021
    Inventors: Adam Johnson, Michael C. Jensen
  • Publication number: 20210324407
    Abstract: Some embodiments provided herein relate to gene delivery systems and methods using a single plasmid that carries a self-inactivating transposase gene and a corresponding transposon. Some embodiments include nucleic acids having certain sequences, vector including such nucleic acids, and compositions including the vectors.
    Type: Application
    Filed: August 28, 2019
    Publication date: October 21, 2021
    Inventors: Michael C. Jensen, Joshua Gustafson, Joseph Cheng, Rachel Wilson, Kamila Sabina Gwiazda, Jeremy Bjelajac
  • Publication number: 20210317407
    Abstract: Some embodiments of the methods and compositions provided herein relate to the use of hapten labeled cells to stimulate chimeric antigen receptor (CAR) T cells. In some embodiments, CAR T cells can include a CAR that specifically binds to a hapten. Some embodiments relate to the in vivo or in vitro stimulation CAR T cells by hapten labeled cells.
    Type: Application
    Filed: August 2, 2019
    Publication date: October 14, 2021
    Inventors: Michael C. Jensen, James F. Matthaei
  • Patent number: 11123369
    Abstract: Disclosed herein are methods of engineering a bi-specific T-cell expressing chimeric antigen receptors for promoting the in vivo expansion and activation of an effector cell and a second chimeric antigen receptor or TcR specific for a ligand on a tumor. Methods of administering to subjects in need, bi-specific chimeric antigen receptor bearing cells are also provided.
    Type: Grant
    Filed: November 3, 2020
    Date of Patent: September 21, 2021
    Assignee: Seattle Children's Hospital
    Inventor: Michael C. Jensen
  • Publication number: 20210269502
    Abstract: The present application relates to fusion proteins, chimeric antigen bearing cells expressing fusion proteins and compositions comprising chimeric antigen bearing cells expressing fusion proteins. The application further relates to methods of using the fusion proteins, cells and compositions for modulating an immune response.
    Type: Application
    Filed: February 2, 2021
    Publication date: September 2, 2021
    Inventors: Michael C. Jensen, Adam Johnson
  • Publication number: 20210145880
    Abstract: A CD19-OR-CD20 chimeric antigen receptor (CAR) protein construct is provided. Also provided are nucleic acids encoding the CD19-OR-CD20 CAR; and methods of use, e.g. in the treatment of B cell malignancies. The CD19-OR-CD20 CAR of the invention is a bispecific CAR that can trigger T-cell activation upon detection of either CD19 or CD20 (or both). It is a single molecule that confers two-input recognition capability upon human T cells engineered to stably express this CAR.
    Type: Application
    Filed: September 22, 2020
    Publication date: May 20, 2021
    Inventors: Yvonne Y. CHEN, Eugenia ZAH, Michael C. JENSEN
  • Publication number: 20210145873
    Abstract: The present invention is directed to mammalian bi-specific T cells and methods for using these bi-specific T cells. More specifically, the invention relates to a method of controlling administration of cancer antigen to a subject by providing bi-specific T cells that express a viral antigen T cell receptor and a cancer antigen-specific chimeric receptors and triggering their activation by also administering antigen-presenting T-cells which express viral antigen. These bi-specific T cell clones are a source of effector cells that persist in vivo in response to stimulation with viral antigen, leading to long-term function after their transfer to patients with cancer and autoimmune diseases.
    Type: Application
    Filed: July 2, 2020
    Publication date: May 20, 2021
    Inventors: Laurence J.N. Cooper, Michael C. Jensen
  • Publication number: 20210139583
    Abstract: Aspects of the invention described herein include methods of treating, inhibiting, ameliorating and/or eliminating a virus or cancer cells in a subject utilizing genetically engineered human T-cells having receptors for a molecule presented by the virus or the cancer cells, wherein the genetically engineered T cells are isolated utilizing a two-stage MTX selection that employs increasing concentrations of MTX.
    Type: Application
    Filed: November 12, 2020
    Publication date: May 13, 2021
    Inventors: Michael C. Jensen, Suzie Pun, Nataly Kacherovsky
  • Patent number: 10968431
    Abstract: The present invention provides a method of carrying out adoptive immunotherapy in a primate subject in need thereof by administering the subject a cytotoxic T lymphocytes (CTL) preparation in a treatment-effective amount. The method comprises administering as the CTL preparation a preparation consisting essentially of an in vitro expanded primate CTL population, the CTL population enriched prior to expansion for central memory T lymphocytes, and depleted prior to expansion of effector memory T lymphocytes. In some embodiments, the method may further comprise concurrently administering Interleukin-15 to the subject in an amount effective to increase the proliferation of the central memory T cells in the subject. Pharmaceutical formulations produced by the method, and methods of using the same, are also described.
    Type: Grant
    Filed: July 17, 2019
    Date of Patent: April 6, 2021
    Assignees: City of Hope, Fred Hutchinson Cancer Research Center
    Inventors: Stanley R. Riddell, Susanna Carolina Berger, Michael C. Jensen
  • Publication number: 20210085719
    Abstract: Disclosed herein are methods of engineering a bi-specific T-cell expressing chimeric antigen receptors for promoting the in vivo expansion and activation of an effector cell and a second chimeric antigen receptor or TcR specific for a ligand on a tumor. Methods of administering to subjects in need, bi-specific chimeric antigen receptor bearing cells are also provided.
    Type: Application
    Filed: November 3, 2020
    Publication date: March 25, 2021
    Inventor: Michael C. Jensen
  • Publication number: 20210052649
    Abstract: The present invention provides nucleic acids, vectors, host cells, methods and compositions to confer and/or augment immune responses mediated by cellular immunotherapy, such as by adoptively transferring CD8+ central memory T cells or combinations of central memory T cells with CD4+ T cells that are genetically modified to express a chimeric receptor. In embodiments the genetically modified host cell comprises a nucleic acid comprising a polynucleotide coding for a ligand binding domain, a polynucleotide comprising a customized spacer region, a polynucleotide comprising a transmembrane domain, and a polynucleotide comprising an intracellular signaling domain. It has been surprisingly found that the length of the spacer region can affects the ability of chimeric receptor modified T cells to recognize target cells in vitro and affects in vivo efficacy of the chimeric receptor modified T cells. Pharmaceutical formulations produced by the method, and methods of using the same, are also described.
    Type: Application
    Filed: September 9, 2020
    Publication date: February 25, 2021
    Inventors: Michael C. Jensen, Stanley R. Riddell, Michael Hudecek
  • Patent number: 10919950
    Abstract: The present application relates to fusion proteins, chimeric antigen bearing cells expressing fusion proteins and compositions comprising chimeric antigen bearing cells expressing fusion proteins. The application further relates to methods of using the fusion proteins, cells and compositions for modulating an immune response.
    Type: Grant
    Filed: January 10, 2017
    Date of Patent: February 16, 2021
    Assignee: Seattle Children's Hospital
    Inventors: Michael C. Jensen, Adam Johnson
  • Publication number: 20210040448
    Abstract: Some embodiments provided herein relate to methods and compositions for making genetically modified T cells. In some such embodiments, CD4+ and CD8+ T cells are cultured in a single serum-free volume. In some embodiments, co-cultured CD4+ and CD8+ T cells can be transduced with a lentiviral vector, and a population of transduced T cells can be harvested within a shorter period of time than other conventional methods.
    Type: Application
    Filed: February 4, 2019
    Publication date: February 11, 2021
    Inventors: Michael C. Jensen, Joshua Gustafson
  • Publication number: 20210017246
    Abstract: Some embodiments of the methods and compositions provided herein include cells having membrane-tethered, IL13 mutein-directed zetakine receptors, such as those which specifically bind to the IL-13 receptor alpha 2 (IL13Ra2) at a 50-fold higher affinity than wild-type IL-13, and methods of cell-based immunotherapy targeting cancer cells, such as cells of solid tumors, using these compositions. In some embodiments, the receptors include spacer regions, such as particular spacer regions designed to provide certain advantages.
    Type: Application
    Filed: March 12, 2019
    Publication date: January 21, 2021
    Inventors: Giacomo Tampella, Michael C. Jensen, Adam Johnson
  • Publication number: 20210000875
    Abstract: Some embodiments of the methods and compositions provided herein relate to chimeric antigen receptors (CARs) that specifically bind to human extracellular domains of the IL-13 alpha 2 (IL13Ra2) receptor, cells containing such CARs, and methods of cell-based immunotherapy targeting cancer cells, such as cells of solid tumors.
    Type: Application
    Filed: March 12, 2019
    Publication date: January 7, 2021
    Inventors: Giacomo Tampella, Michael C. Jensen
  • Publication number: 20210002364
    Abstract: The present invention provides genetic tags operably linked to transgenes. The expression of the genetic tag allows identification, detection, selection, and ablation of cells expressing the transgene and the genetic tag. In some alternatives the genetically modified host cell comprises a transgene comprising a polynucleotide coding for a chimeric antigen receptor comprising a ligand binding domain, a polynucleotide comprising a spacer region, a polynucleotide comprising a transmembrane domain, and a polynucleotide comprising an intracellular signaling domain and a polynucleotide coding for a genetic tag.
    Type: Application
    Filed: February 19, 2020
    Publication date: January 7, 2021
    Inventors: Michael C. Jensen, Adam Johnson